Literature DB >> 32382830

Gout: a disease involved with complicated immunoinflammatory responses: a narrative review.

Meimei Wu1,2, Ye Tian2,3,4, Qianqian Wang2,3,4, Chengshan Guo5,6,7.   

Abstract

Gout is a disease with acute and/or chronic inflammation and tissue damage induced by the precipitation of monosodium urate crystal (MSU) crystals in bone joints, kidneys, and subcutaneous sites. In recent years, with the continuous research on gout animal models and patient clinical investigations, the mechanism of inflammation activation of gout has been further discovered. Studies have shown that pro-inflammatory factors such as interleukin (IL)-1β, IL-8 and IL-17, NLRP3 inflammasome, and tumor necrosis factor alpha (TNF-α), anti-inflammatory factors such as IL-10, IL-37 are all involved in the MSU-induced gout inflammatory process. And the immune cells in gout, including neutrophils, monocytes/macrophages, and lymphocytes, all play important roles in the pathogenesis of gout. In this review, we mainly emphasize the understanding of various cytokines, inflammasome, and immune cells involved in the onset of gout, in order to provide a systematic and theoretical basis for the novel exploration of inflammatory therapeutic targets for gout.

Entities:  

Keywords:  Gout; Immune cell; Inflammasome; Interleukin; Monosodium urate; Tumor necrosis factor alpha

Mesh:

Substances:

Year:  2020        PMID: 32382830     DOI: 10.1007/s10067-020-05090-8

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  8 in total

Review 1.  Potential Molecular Mechanisms of Plantain in the Treatment of Gout and Hyperuricemia Based on Network Pharmacology.

Authors:  Pei Liu; Huachong Xu; Yucong Shi; Li Deng; Xiaoyin Chen
Journal:  Evid Based Complement Alternat Med       Date:  2020-10-22       Impact factor: 2.629

Review 2.  Genetic Variants in Transcription Factor Binding Sites in Humans: Triggered by Natural Selection and Triggers of Diseases.

Authors:  Chia-Chun Tseng; Man-Chun Wong; Wei-Ting Liao; Chung-Jen Chen; Su-Chen Lee; Jeng-Hsien Yen; Shun-Jen Chang
Journal:  Int J Mol Sci       Date:  2021-04-18       Impact factor: 5.923

3.  Galectin-9 Regulates Monosodium Urate Crystal-Induced Gouty Inflammation Through the Modulation of Treg/Th17 Ratio.

Authors:  Adel Abo Mansour; Federica Raucci; Anella Saviano; Samantha Tull; Francesco Maione; Asif Jilani Iqbal
Journal:  Front Immunol       Date:  2021-10-28       Impact factor: 7.561

4.  A Hypothesis Regarding Neurosecretory Inhibition of Stress Mediators by Colchicine in Preventing Stress-Induced Familial Mediterranean Fever Attacks.

Authors:  Cengiz Korkmaz; Döndü Üsküdar Cansu; Güven Barıs Cansu
Journal:  Front Immunol       Date:  2022-02-17       Impact factor: 7.561

5.  Characterization of Plasma Extrachromosomal Circular DNA in Gouty Arthritis.

Authors:  Jingyuan Pang; Xiaoguang Pan; Ling Lin; Lei Li; Shuai Yuan; Peng Han; Xiaopeng Ji; Hailong Li; Can Wang; Zhaobin Chu; Haoru Wu; Guangyi Fan; Xiao Du; Aichang Ji
Journal:  Front Genet       Date:  2022-04-06       Impact factor: 4.772

6.  Potential molecular mechanisms of Ermiao san in the treatment of hyperuricemia and gout based on network pharmacology with molecular docking.

Authors:  Yin-Hong Geng; Jia-Hui Yan; Liang Han; Zhe Chen; Sheng-Hao Tu; Lin-Qi Zhang; Chun-Dong Song; Feng-Yang Duan; Ya-Fei Liu
Journal:  Medicine (Baltimore)       Date:  2022-09-16       Impact factor: 1.817

7.  Exploring RNA modifications, editing, and splicing changes in hyperuricemia and gout.

Authors:  Chung-Ming Huang; Yu-Chia Chen; I-Lu Lai; Hong-Da Chen; Po-Hao Huang; Siang-Jyun Tu; Ya-Ting Lee; Ju-Chen Yen; Chia-Li Lin; Ting-Yuan Liu; Jan-Gowth Chang
Journal:  Front Med (Lausanne)       Date:  2022-09-06

8.  Mechanism Investigation of Wuwei Shexiang Pills on Gouty Arthritis via Network Pharmacology, Molecule Docking, and Pharmacological Verification.

Authors:  Jirui Lang; Li Li; Shilong Chen; Yunyun Quan; Jing Yi; Jin Zeng; Yong Li; Junning Zhao; Zhujun Yin
Journal:  Evid Based Complement Alternat Med       Date:  2022-10-07       Impact factor: 2.650

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.